SEC EDGARSep 4$HTFL

Verghese Vikram sold $1.7M of HTFL

Verghese Vikram (Chief Financial Officer) sold 33,416 shares of Heartflow, Inc. (HTFL) at an average of $49.85 ($49.69–$50.60, $1.67M total) across 2 trades over 2026-09-02 to 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Verghese Vikram

Published Sep 4, 2026, 9:29 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 4, 2026, 9:31 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HTFL

Bearish

medium confidence

Mentioned

$HTFL

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HTFLBearishLow

Why it matters

The CFO's sale reduces insider ownership, which may be interpreted as a lack of confidence, but the modest size limits market impact.

Market read

Insider sale news provides a modest bearish cue for HTFL traders.

What to watch

Potential upcoming clinical data releases or partnership announcements could offset the negative signal.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑09‑04

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HTFLBearishMedium confidence

Context

CFO Verghese Vikram sold 33,416 shares for $1.66M via a 10b5‑1 plan, reducing his stake to 221,143 shares.

Expected impact

Short‑term downward pressure; price may dip modestly on the news.

Evidence & confidence

The sale size is modest relative to market cap, but CFO involvement and use of a pre‑arranged plan suggest a neutral‑to‑negative bias.

Market effects

Sector

Minimal; the sale does not affect the broader cardiovascular diagnostics sector.

Regional

None; the filing is company‑specific.

Global

Low; only relevant to investors in HTFL.

Counterpoint

What could challenge this read

The CFO may be liquidating for personal reasons unrelated to company outlook; the sale could be neutral.

Key entities

Company
Heartflow, Inc.
Medical device company listed on NASDAQ under HTFL.
Executive
Verghese Vikram
Chief Financial Officer of Heartflow.

Read at source ← All news

Med

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

finance.yahoo.comNov 14

Med

Canaccord Genuity maintains HeartFlow at Buy, raises price target to $69 from $56

Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.

tradingview.comNov 13

High

Stifel maintains HeartFlow at Buy, raises price target to $70 from $45

Stifel upgraded its price target for HeartFlow to $70 from $45, a 55.6% increase, implying 16.8% upside from the Nov 12 close of $59.92. The firm maintained its Buy rating on the company.

tradingview.comNov 13

$HTFLMed

Stifel raises HeartFlow stock price target to $70 on strong growth

Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.

investing.comNov 13

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

finance.yahoo.comNov 13

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.